After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well ...
The Quebec Society of Vascular Sciences (QSVS) is launching a new conversational AI-powered tool, AmelIA, to its Vascular Health Portal, This initiative, developed in partnership with Boehringer ...
German family-owned pharma major Boehringer Ingelheim and AimedBio, a Korean biotech company pioneering antibody-drug ...
Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...
An individual patient-level meta-analysis shows that tenecteplase, a next-generation thrombolytic, is at least as effective ...
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...
According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ ...
As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...
Boehringer Ingelheim unveiled its evolved company brand this week, featuring the corporate claim: “Life forward.” The German pharma giant said the claim builds upon the company’s purpose of ...
INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech ...
INGELHEIM, Germany & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim announced today a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback